Vistagen Therapeutics (VTGN) Stock Forecast & Price Target

$2.61 -0.06 (-2.25%)

(As of 11/20/2024 ET)

Vistagen Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Strong Buy

Based on 2 Analyst Ratings

Sell
0

Hold
0

Buy
2

Based on 2 Wall Street analysts who have issued ratings for Vistagen Therapeutics in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 1 has given a buy rating, and 1 has given a strong buy rating for VTGN.

Consensus Price Target

$15.00
474.71% Upside

According to the 2 analysts' twelve-month price targets for Vistagen Therapeutics, the average price target is $15.00. The highest price target for VTGN is $15.00, while the lowest price target for VTGN is $15.00. The average price target represents a forecasted upside of 474.71% from the current price of $2.61.

Get the Latest News and Ratings for VTGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vistagen Therapeutics and its competitors.

VTGN Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$15.00	$13.50	$19.00	$21.00
Forecasted Upside	474.71% Upside	335.48% Upside	417.71% Upside	526.87% Upside
Consensus Rating	Strong Buy	Buy	Buy	Buy

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

VTGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VTGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vistagen Therapeutics Stock vs. The Competition

Type	Vistagen Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.50	2.80	2.50
Consensus Rating	Strong Buy	Moderate Buy	Moderate Buy
Predicted Upside	474.71% Upside	26,904.61% Upside	9.81% Upside
News Sentiment Rating	Very Positive News See Recent VTGN News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/30/2024	William Blair 2 of 5 stars	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/7/2023	Jefferies Financial Group 2 of 5 stars		Upgrade	Hold ➝ Buy	$15.00	+238.60%
11/14/2023	Stifel Nicolaus 4 of 5 stars		Initiated Coverage	Buy	$12.00	+275.00%
9/5/2023	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$30.00	+393.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:38 AM ET.

VTGN Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Vistagen Therapeutics is $15.00, with a high forecast of $15.00 and a low forecast of $15.00.
: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last twelve months. There is currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" VTGN shares.
: According to analysts, Vistagen Therapeutics's stock has a predicted upside of 474.71% based on their 12-month stock forecasts.
: Over the previous 90 days, Vistagen Therapeutics's stock had 1 upgrade by analysts.
: Vistagen Therapeutics has been rated by research analysts at William Blair in the past 90 days.
: Analysts like Vistagen Therapeutics more than other "medical" companies. The consensus rating for Vistagen Therapeutics is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VTGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Use this link to see Nvidia Unchained right away!

This page (NASDAQ:VTGN) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vistagen Therapeutics (VTGN) Stock Forecast & Price Target